New: our quarterly report on the S&P 500, read from 500 companies’ own filings and calls.
Read the Q3 2026 report
Friday, Nov 20, 2026
Export MRK’s income statement to Excel — free account
Merck & Co., Inc.
MRKHealthcare Drug Manufacturers General
Merck & Co., Inc.’s revenue for fiscal 2025 (year ended December 2025) was $65.0 billion, up 1.31% from fiscal 2024.
- Revenue
- +4.68%
- EPS
- −12.1%
- Free cash flow
- −19.3%
- Total debt
- +24.3%
Quarter to September 2026, against a year earlier
135.30
2.56
+1.93%
Follow MRK
Alert me
Analysts’ price targets Wall Street, collected weekly
Analyst price targets
Free accountTen years at a glance Fiscal years to December
| Ten-year view | Analyst estimates Powerpack | |||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Group | Line | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM Sep ’26 | Trend | 10 yrs | 2026e | 2027e | 2028e | Next 3/yr |
| Income, $m | ||||||||||||||||||
| Income, $m | Revenue | 39,807 | 40,122 | 42,294 | 39,121 | 41,518 | 48,704 | 59,283 | 60,115 | 64,168 | 65,011 | 67,378 | +5.6% | 67,242 | 69,461 | 73,744 | +4.3% | |
| Gross margin, % | 64.75 | 67.82 | 68.06 | 69.29 | 67.20 | 72.02 | 70.63 | 73.17 | 76.32 | 74.80 | 71.75 | +10.1 pt | ||||||
| EBT | 4,659 | 6,521 | 8,701 | 7,171 | 5,863 | 13,879 | 16,444 | 1,889 | 19,936 | 21,067 | 4,762 | +18.3% | ||||||
| EBT margin, % | 11.70 | 16.25 | 20.57 | 18.33 | 14.12 | 28.50 | 27.74 | 3.14 | 31.07 | 32.41 | 7.07 | +20.7 pt | ||||||
| Net income | 3,941 | 2,418 | 6,193 | 5,606 | 4,523 | 12,358 | 14,526 | 377 | 17,133 | 18,263 | 2,449 | +18.6% | ||||||
| Per share, $ | ||||||||||||||||||
| Per share, $ | Revenue | 14.39 | 14.70 | 15.88 | 15.25 | 16.41 | 19.25 | 23.41 | 23.70 | 25.34 | 25.98 | 27.30 | +6.8% | |||||
| Earnings | 1.42 | 0.93 | 2.32 | 3.81 | 2.78 | 5.16 | 5.73 | 0.14 | 6.74 | 7.28 | 0.97 | +19.9% | ||||||
| Cash flow | 3.75 | 2.36 | 4.10 | 3.46 | 3.01 | 5.19 | 7.54 | 5.13 | 8.48 | 6.58 | 7.58 | +6.4% | ||||||
| Capex | (0.58) | (0.69) | (0.98) | (1.31) | (1.75) | (1.76) | (1.73) | (1.52) | (1.33) | (1.64) | (1.60) | +12.2% | ||||||
| Free cash flow | 3.17 | 1.67 | 3.12 | 2.15 | 1.26 | 3.43 | 5.81 | 3.60 | 7.15 | 4.94 | 5.97 | +5.1% | ||||||
| Book value | 14.57 | 12.66 | 10.09 | 10.14 | 10.04 | 15.12 | 18.19 | 14.83 | 18.31 | 21.05 | 18.21 | +4.2% | ||||||
| Shares, m | 2,766 | 2,730 | 2,664 | 2,565 | 2,530 | 2,530 | 2,532 | 2,537 | 2,532 | 2,502 | 2,478 | (1.1%) | ||||||
| Valuation, × | ||||||||||||||||||
| Valuation, × | P/E | 41.49 | 58.34 | 31.78 | 23.04 | 28.50 | 14.85 | 19.40 | 808.86 | 14.78 | 14.46 | 136.85 | 105.5 | |||||
| P/S | 4.03 | 3.69 | 4.64 | 5.75 | 4.81 | 3.98 | 4.75 | 4.78 | 3.93 | 4.05 | 4.86 | 4.4 | ||||||
| P/B | 3.98 | 4.29 | 7.31 | 8.66 | 7.86 | 5.07 | 6.11 | 7.63 | 5.43 | 5.00 | 7.29 | 6.1 | ||||||
| EV/Sales | 4.28 | 4.01 | 4.90 | 6.07 | 5.23 | 4.45 | 5.01 | 5.22 | 4.25 | 4.55 | 5.46 | 4.8 | ||||||
| EV/FCF | 19.46 | 35.28 | 24.97 | 43.05 | 68.08 | 24.96 | 20.19 | 34.33 | 15.07 | 23.91 | 24.93 | 30.9 | ||||||
| Cash, $m | ||||||||||||||||||
| Cash, $m | Operating cash flow | 10,376 | 6,451 | 10,922 | 8,884 | 7,617 | 13,122 | 19,095 | 13,006 | 21,468 | 16,472 | 18,703 | +5.3% | |||||
| Capex | (1,614) | (1,888) | (2,615) | (3,369) | (4,429) | (4,448) | (4,388) | (3,863) | (3,372) | (4,112) | (3,957) | +11.0% | ||||||
| Free cash flow | 8,762 | 4,563 | 8,307 | 5,515 | 3,188 | 8,674 | 14,707 | 9,143 | 18,096 | 12,360 | 14,746 | +3.9% | ||||||
| Balance, $m | ||||||||||||||||||
| Balance, $m | Working capital | 13,410 | 6,152 | 3,669 | 5,263 | 437 | 6,394 | 11,483 | 6,474 | 10,362 | 15,189 | 10,140 | +1.4% | |||||
| Net debt | 9,933 | 12,855 | 10,942 | 12,286 | 17,310 | 22,594 | 15,553 | 26,590 | 20,773 | 32,185 | 40,039 | +14.0% | ||||||
| Shareholders’ equity | 40,308 | 34,569 | 26,882 | 26,001 | 25,404 | 38,257 | 46,058 | 37,635 | 46,372 | 52,662 | 44,946 | +3.0% | ||||||
| Returns, % | ||||||||||||||||||
| Returns, % | ROA | 3.98 | 2.61 | 7.30 | 11.79 | 8.03 | 13.23 | 13.52 | 0.34 | 15.30 | 14.37 | 1.87 | +10.4 pt | |||||
| ROIC | 6.84 | 8.96 | 14.76 | 12.94 | 8.12 | 13.56 | 18.55 | 2.87 | 18.82 | 16.28 | 4.56 | +9.4 pt | ||||||
| ROE | 9.22 | 6.39 | 20.24 | 37.23 | 27.50 | 41.00 | 34.44 | 0.87 | 40.75 | 36.86 | 5.07 | +27.6 pt | ||||||
| People | ||||||||||||||||||
| People | Employees | 68,000 | 69,000 | 69,000 | 71,000 | 74,000 | 68,000 | 69,000 | 72,000 | 75,000 | 75,000 | — | +1.1% | |||||
| Revenue/emp, $m | 0.59 | 0.58 | 0.61 | 0.55 | 0.56 | 0.72 | 0.86 | 0.83 | 0.86 | 0.87 | — | +4.5% | ||||||
Negative figures in brackets.
estimates
Fiscal years to Dec 2025 · latest quarter Sep 2026 · fundamentals updated Nov 18, 2026
Business profile
Where the money comes from and where it goes Fiscal 2025
| Pharmaceutical | 58,142 | 89.43% |
|---|---|---|
| Animal Health | 6,354 | 9.77% |
| Other, not broken out | 515 | 0.79% |
| Gross margin | 74.80% | |
| Operating margin | 34.01% | |
| Pre-tax margin | 32.41% |
Merck & Co., Inc. vs peers in Drug Manufacturers General (Q) = latest quarter vs a year earlier
| Company | Market cap | P/E | Fwd P/E | Revenue growth (Q) | EPS growth (Q) | FCF growth (Q) | Gross margin (Q) | EBIT margin (Q) | Compare |
|---|---|---|---|---|---|---|---|---|---|
| JNJ Johnson & Johnson | $650.7B | 40.5× | 41.8× FY26e | +5.86% (above 0%: growing) | −95.75% (below 0%: shrinking) | −21.44% (below 0%: shrinking) | 68.12% | 1.72% | Compare |
| ABBV AbbVie Inc. | $501.2B | 48.8× | 37.6× FY26e | +10.32% (above 0%: growing) | +2,270.00% (above 0%: growing) | +9.97% (above 0%: growing) | 75.38% | 36.01% | Compare |
| MRK Merck & Co., Inc. | $328.6B | 137× | 105× FY26e | +4.68% (above 0%: growing) | −12.07% (below 0%: shrinking) | −19.27% (below 0%: shrinking) | 72.95% | 31.90% | |
| NVS Novartis AG | $277.7B | 28.8× | 24.0× FY26e | +4.67% (above 0%: growing) | −68.81% (below 0%: shrinking) | −17.81% (below 0%: shrinking) | 75.99% | 12.26% | Compare |
| AZN AstraZeneca PLC | $272.1B | 24.6× | 24.2× FY26e | +6.70% (above 0%: growing) | +23.46% (above 0%: growing) | +1.99% (above 0%: growing) | 81.82% | 27.07% | Compare |
| AMGN Amgen Inc. | $237.4B | 25.2× | 24.0× FY26e | +8.45% (above 0%: growing) | +19.39% (above 0%: growing) | −13.98% (below 0%: shrinking) | 73.10% | 35.79% | Compare |
| GILD Gilead Sciences, Inc. | $207.8B | — (loss-making) | — (loss-making) | +6.83% (above 0%: growing) | −20.16% (below 0%: shrinking) | +21.13% (above 0%: growing) | 81.07% | 41.71% | Compare |
| PFE Pfizer Inc. | $158.2B | 38.8× | 18.7× FY26e | −0.43% (below 0%: shrinking) | −9.68% (below 0%: shrinking) | +20.02% (above 0%: growing) | 75.71% | 22.14% | Compare |
| NVO Novo Nordisk A/S | $128.6B | 9.8× | — | +3.87% (above 0%: growing) | −17.14% (below 0%: shrinking) | −14.75% (below 0%: shrinking) | 76.97% | 29.06% | Compare |
| Median of peers | $254.7B | 28.8× | 24.1× | +6.28% | −13.41% | −5.99% | 75.85% | 28.07% |
From the latest earnings call
- CFO Caroline Litchfield said favorable purchase timing lifted third-quarter sales, with the Keytruda and Winrevair benefits expected to unwind in the fourth quarter.
- Litchfield described 2027 as an investment year, with new products and animal health growth partly offset by generic competition and losses of exclusivity.
Largest institutional holders 13F, quarter to Jun 30, 2026
Held by institutions
79.89%
Held by the ten largest
39.76%
| Holder | Shares | Stake | Change |
|---|---|---|---|
| Vanguard | 255.74m | 10.37% | +1.23m |
| BlackRock | 227.00m | 9.20% | +1.17m |
| State Street | 120.41m | 4.88% | +1.09m |
| Wellington Management | 86.25m | 3.50% | +1.93m |
| Geode Capital Management | 60.74m | 2.46% | +1.19m |
| Charles Schwab | 54.37m | 2.20% | +4.60m |
| Morgan Stanley | 48.64m | 1.97% | +1.01m |
| Fidelity (FMR) | 45.44m | 1.84% | +924.35k |
| JPMorgan Chase | 43.89m | 1.78% | −9.09m |
| Fisher Investments | 38.52m | 1.56% | +12.08m |
13F filings for the quarter to 30 June 2026: long positions in US-listed shares reported by managers with $100m or more, ~45 days after the quarter.
Merck & Co., Inc. (MRK) Latest News
What happened
- Deal Merck entered a research collaboration with Isomorphic Labs to design small-molecule candidates for an undisclosed oncology target.
- Legal A German higher regional court overturned a preliminary injunction that had barred Merck from offering or distributing Keytruda SC in Germany.
- Other Merck discontinued nemtabrutinib development and its Phase 3 BELLWAVE trials after reviews concluded the benefit-risk profile did not support continuing.
- Other Merck received positive EU CHMP opinions for Welireg with lenvatinib in advanced kidney cancer and an expanded Enflonsia indication for vulnerable children up to 24 months.
- Results Merck reported third-quarter sales of $18.1 billion, up 5%, and raised its 2026 guidance.
- Merck & Co., Inc. Q3 2026 Earnings Call Summary Moby
- Merck (MRK) Turns Heads With Phase 3 Endometrial Cancer Data And FDA Review Simply Wall St.
- Merck (MRK) Q3 2026 Earnings Call Transcript The Motley Fool transcript
- Merck Lifts Outlook on a Lower Tax Rate: Rapid Earnings Reaction The Motley Fool
- Merck shares rise over 5% as drugmaker raises sales outlook Proactive Investors
- Merck Rises 5% as Earnings Beat Lifts Profit Outlook; Eli Lilly Climbs 7%, Johnson & Johnson Edges Higher 24/7 Wall St.
- MRK Q3 Earnings & Sales Beat Estimates, '26 EPS View Raised, Stock Up Zacks
- Merck Jumps Nearly 5% on Q3 Beat and Raised Outlook as CEO Touts “Potentially Practice-Changing” Pipeline TIKR
- Merck Reports Q3 Revenue of $18.1 Billion, Raises 2026 Earnings Guidance InvestorsHub
- Merck Opens €300 Million Asia-Pacific Bioprocessing Production Center in Daejeon, South Korea GlobeNewswire
17 more headlines
- Merck’s Keytruda Combo Cut Melanoma Recurrence or Death Risk 42%. What the February 2 Report Has to Prove TIKR
- Merck Announces Positive Results from Phase 2b Trial of Efinopegdutide in Adults with Metabolic Dysfunction-Associated Steatohepatitis (MASH) and Stage 2-3 Fibrosis Business Wire +1 report
- Merck Stock Shows Sustained Strength: Time to Buy, Sell or Hold? Zacks
- MRK's Keytruda & Gardasil Sales Rise in Q3: Can the Momentum Last? Zacks
- Merck & Co. Stock: Is Wall Street Bullish or Bearish? Barchart
- Merck’s Pipeline Could Be Its Next Big Growth Driver. Its Latest Earnings Offer a Clue. 24/7 Wall St.
- Is Cancer And HIV Trial Wins Altering The Investment Case For Merck (MRK)? Simply Wall St.
- Merck stock rises as its cancer strategy gets personal TheStreet
- MRK Q3 deep dive: oncology launches, clinical pipeline advances, and margin headwinds StockStory
- Merck (MRK) Stock Rallies As Q3 Earnings Ease Profit Squeeze Simply Wall St.
- Merck Q3 Earnings Call Highlights Pipeline Progress and Raised Outlook Zacks
- Merck & Co., Inc. Q3 Earnings Call Highlights MarketBeat transcript
- Merck Manuals Helps Patients Navigate the Different Types of Sunscreens PR Newswire
- Merck (NYSE:MRK) delivers impressive Q3 2026 StockStory
- Merck shares rise on Q3 beat, raised 2026 profit outlook Investing.com
- Merck (MRK) Surpasses Q3 Earnings and Revenue Estimates Zacks
- Merck: Q3 Earnings Snapshot Associated Press
MRK metrics, ten years each
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
Merck & Co. is a global health care company that sells prescription medicines, vaccines and animal health products. Founded in 1891, it is headquartered in Rahway and led by Chairman, President and Chief Executive Officer Robert M. Davis.
Its human health business includes medicines for cancer, pulmonary arterial hypertension, diabetes, infections and other conditions. Keytruda, its cancer therapy, is given intravenously; Keytruda Qlex combines the same active cancer medicine with an ingredient that enables an injection under the skin. Merck also sells vaccines, including Gardasil for diseases caused by certain types of human papillomavirus, or HPV.